Skip to content

Tom Kennedy

3 papers in the library · 52 citations · publishing 2023-2025

Papers

Sort Most recent Most cited

Psilocybin-Assisted suppoRtive psychoTherapy IN the treatment of prolonged Grief (PARTING) trial: protocol for an open-label pilot trial for cancer-related bereavement

BMJ Open April 1, 2025 Vanessa L. Beesley, Tom Kennedy, Fiona Maccallum et al. 2 citations

Introduction Prolonged grief disorder (PGD) represents a substantial public health issue, especially in oncology settings where it affects up to 30% of bereaved carers. Current best-practice treatments are lengthy, and up to 50% of participants have persistent PGD. Building on encouraging recent research with psychedelic-assisted therapies, the Psilocybin-Assisted suppoRtive psychoTherapy IN...

Ayahuasca and Dimethyltryptamine Adverse Events and Toxicity Analysis: A Systematic Thematic Review.

International journal of toxicology 2024 Eleanor White, Tom Kennedy, Simon Ruffell et al. 13 citations

The objective of this paper is to conduct a systematic thematic review of adverse events, safety, and toxicity of traditional ayahuasca plant preparations and its main psychoactive alkaloids (dimethyltryptamine [DMT], harmine, harmaline, and tetrahydroharmine), including discussing clinical considerations (within clinical trials or approved settings). A systematic literature search of...

Ayahuasca: A review of historical, pharmacological, and therapeutic aspects.

PCN reports : psychiatry and clinical neurosciences December 1, 2023 Simon Ruffell, Max Crosland-Wood, Rob Palmer et al. 37 citations

Ayahuasca is a psychedelic plant brew originating from the Amazon rainforest. It is formed from two basic components, the Banisteriopsis caapi vine and a plant containing the potent psychedelic dimethyltryptamine (DMT), usually Psychotria viridis. Here we review the history of ayahuasca and describe recent work on its pharmacology, phenomenological responses, and clinical applications. There...